Acute-on-Chronic Liver Failure Management

Causes and Precipitating Factors

• Infection is the most common precipitant of Acute-on-Chronic Liver Failure (ACLF) worldwide, occurring in 48% of cases, followed by active alcohol use and hepatitis B flares, according to the European Association for the Study of the Liver 1
• Bacterial infections are the leading cause, with spontaneous bacterial peritonitis (SBP), urinary tract infections, and skin/soft-tissue infections being most common, as stated by the European Association for the Study of the Liver 1
• Active alcoholism with superimposed alcoholic hepatitis represents a major precipitant, particularly in Western populations, as noted by the American Association for the Study of Liver Diseases 1
• Gastrointestinal bleeding can trigger ACLF through hemodynamic instability and increased infection risk, according to the American College of Gastroenterology 2
• Drug toxicity, including acetaminophen and other hepatotoxic medications, can also precipitate ACLF, as warned by the American Association for the Study of Liver Diseases 3

Patient Populations at High Risk

• Younger male patients with alcohol-associated cirrhosis and high MELD scores are at greatest risk, as identified by the European Association for the Study of the Liver 1
• Patients with invasive procedures, indwelling lines, and catheters face increased infection risk, according to the Centers for Disease Control and Prevention 1
• Multi-drug-resistant (MDR) organisms substantially increase both ACLF risk and mortality, as reported by the World Health Organization 1

Management Strategies

• Diagnose and treat precipitating factors immediately, particularly bacterial infections with empirical broad-spectrum antibiotics for patients with worsening hepatic encephalopathy or signs of systemic inflammatory response syndrome (SIRS), as recommended by the Infectious Diseases Society of America 1
• Empirical broad-spectrum antibiotics should be administered immediately to patients with worsening hepatic encephalopathy or SIRS criteria, as advised by the European Association for the Study of the Liver 1
• Maintain high suspicion for sepsis even without fever, as fever is often absent in cirrhotic patients with infection, according to the Society of Critical Care Medicine 1
• Biomarkers (C-reactive protein, procalcitonin, lactate) are frequently elevated in cirrhosis regardless of infection, but persistent elevation indicates poor prognosis, as noted by the American Association for the Study of Liver Diseases 1

Hepatorenal Syndrome and Acute Kidney Injury Management

• For Stage 2 or greater HRS-AKI, initiate vasoconstrictors (terlipressin 0.5-2.0 mg IV q6h or norepinephrine) plus albumin (20-40 g/day) after withdrawing diuretics and volume resuscitation with IV albumin 1 g/kg (maximum 100 g/day) for 48 hours, as recommended by the European Association for the Study of the Liver 1
• Withdraw diuretics and treat precipitating factors (infection, bleeding), according to the American College of Nephrology 1
• Volume challenge with IV albumin at 1 g/kg body weight (maximum 100 g/day) for 48 hours, as advised by the European Renal Association 1

Respiratory Management

• For acute hypoxemic respiratory failure, consider high-flow nasal cannula (HFNC) with close monitoring for escalation to mechanical ventilation if tachypnea or refractory hypoxemia develops, as recommended by the American Thoracic Society 4
• Lung protective ventilation with tidal volume 6 mL/kg predicted body weight (PBW) and plateau pressure <30 cm H2O for acute lung injury (ALI)/ARDS, according to the Society of Critical Care Medicine 4

Hemodynamic Support

• Norepinephrine is the first-line vasopressor for persistent hypotension after fluid resuscitation, with crystalloids as the initial fluid of choice, as recommended by the American College of Cardiology 2
• Monitor hemodynamic function continuously and avoid excessive volume expansion that worsens organ function, according to the European Society of Cardiology 2

Hepatic Encephalopathy Management

• Treat hepatic encephalopathy with lactulose (oral or rectal) or polyethylene glycol if ileus/abdominal distention is a concern, and consider ICU admission for Grade 3-4 encephalopathy, as advised by the American Association for the Study of Liver Diseases 2
• Maintain serum sodium 140-145 mmol/L to prevent cerebral edema, according to the European Association for the Study of the Liver 3

Coagulation Management

• Do NOT routinely correct coagulation abnormalities unless active bleeding is present, as clotting factor administration can worsen outcomes, as warned by the American Association for the Study of Liver Diseases 3
• Restrict fresh frozen plasma and platelet transfusions to cases of active hemorrhage, according to the American College of Surgeons 3

Liver Transplantation

• Early referral to a liver transplant center for immediate evaluation is mandatory for all ACLF patients, as transplantation is the definitive treatment but must be weighed against multiorgan failure severity, as recommended by the United Network for Organ Sharing 1
• ACLF-2 or ACLF-3 patients require urgent transplant assessment, according to the American Association for the Study of Liver Diseases 2

Plasma Exchange

• Plasma exchange is NOT recommended for routine ACLF management outside research trials, despite emerging data showing potential benefit, as stated by the European Association for the Study of the Liver 5
• The European Association for the Study of the Liver explicitly recommends against routine plasma exchange for ACLF, according to the European Association for the Study of the Liver 5

Acute-on-Chronic Liver Failure (ACLF) Management

Introduction to ACLF Management

• The European Association for the Study of the Liver (EASL) recommends that patients with ACLF should be ideally admitted to intensive care or intermediate units, with individualized decision-making based on age and comorbidities 6
• Early referral to a transplant center is mandatory for all patients with ACLF, as rapid progression can make transplantation impossible if delayed 6, 7

Organ Support

• The American Association for the Study of Liver Diseases (AASLD) suggests that norepinephrine is the first-line vasopressor for persistent hypotension after fluid resuscitation, with crystalloids as the initial fluid of choice 8, 9, 10
• The European Society of Intensive Care Medicine recommends that terlipressin should be administered with caution in patients with ACLF-3 due to the increased risk of respiratory failure 8, 9, 10

Respiratory Management

• The American Thoracic Society recommends that for acute hypoxemic respiratory failure, consider high-flow nasal cannula (HFNC) with close monitoring for escalation to invasive mechanical ventilation if tachypnea or refractory hypoxemia occurs 8, 9, 10
• Investigate and treat pulmonary comorbidities related to cirrhosis (hydrothorax, ascites, hepatopulmonary syndrome) 8, 9, 10

Specific Treatments

• The American Association for the Study of Liver Diseases (AASLD) recommends that antiviral therapy with nucleoside analogs (tenofovir, entecavir) should be instituted as soon as possible in patients with ACLF due to hepatitis B infection 6, 7
• Reactivation of hepatitis B is a very common cause of ACLF in certain parts of the world, particularly in Southwest Asia 7

Transplantation

• The European Association for the Study of the Liver (EASL) recommends that early referral to a liver transplant center for immediate evaluation is mandatory for all patients with ACLF, as transplantation is the definitive treatment 7, 11
• The 1-year survival rate for patients with ACLF who receive early transplantation is 78%, compared to <10% without transplantation 11

Prognostic Evaluation

• Reevaluation of the ACLF grade at 3-7 days can predict outcome, with improvement in organ function indicating potential for recovery, and worsening or stable multi-organ failure indicating the need for urgent transplantation 11
• A CLIF-C ACLF score >70 at admission or on day 3 was associated with approximately 90% mortality at 90 days 11